Twitter Facebook LinkedIn YouTube

New Listing: Appili Therapeutics (TSXV:APLI)

Video Platform Video Management Video Solutions Video Player

Appili, a pharmaceutical company, is focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease.

Additional Information:

Company: Appili Therapeutics
Stock Symbol: TSXV: APLI
Date Published: Jun 27, 2019
Transcript: Available

Video Transcript:

I’m Cassandra Bolinski for Investmentpitch Media

Appili Therapeutics is one of the latest new listings on the TSX Venture Exchange, trading under the symbol “APLI”.

Appili, a pharmaceutical company, is focused on the acquisition and development of novel treatments targeting unmet needs in infectious disease.

Appili has built a pipeline of 3 programs with multiple near-term milestones designed to address a broad range of significant unmet medical needs in the infectious disease landscape.

Via an in-licensing program, Appili acquired the rights to ATI-1701, a vaccine for tularemia, being developed to mitigate the risks of a very serious biological weapons threat.

Francisella tularensis is 1,000 times more infectious than anthrax, is easily dispersed and there is currently no FDA approved vaccine available

The Defense Threat Reduction Agency, part of the U.S. Department of Defense, has provided over US$6 million to date to support the development work on the ATI-1701 vaccine.

ATI-1503 is Appili’s negamycin program, a new class of broad-spectrum antibiotics targeting multi-drug resistant, Gram-negative bacteria.

With death rates from multi-drug resistant bacteria expected to surpass cancer by 2050, better options to combat this threat are one of the most urgent unmet patient needs in today’s medical landscape.

The company’s ATI-1501, a proprietary taste-masked liquid suspension reformulation of metronidazole, is designed to enable broader use of metronidazole among patients with difficulty swallowing.

Metronidazole is a widely used front-line oral treatment used to treat parasitic and anaerobic bacterial infections with over 10 million prescriptions written in the United States every year.

Unfortunately, a sizeable and growing number of patients, including children and the elderly, and others who have difficulty swallowing, have difficulty taking the tablet form of the drug, which is the only approved oral form on the U.S. market.

Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, the company is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments, and government agencies.

In addition to working with these organizations, the company is actively seeking partners for commercialization of our lead program, ATI-1501, as well as engaging with other biopharma companies and government organizations to identify additional in-licensing opportunities that meet its business criteria.

The company raised gross proceeds of $3.6 million through an IPO which qualified the distribution of approximately 3,250,000 shares at an implied price of $1.10 following a share split, with Mackie Research, Echelon Wealth and Bloom Burton acting as agents on the offering.

The shares are currently trading at $0.90.

For more information, please visit the company’s website, contact Kevin Sullivan, CEO at 902-442-4655 ext 1, or email

For investor relations contact Kimberley Stephens, CFO, at

I’m Cassandra Bolinski for Investmentpitch Media